You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝康醫療-B(02170.HK):公司與美國GATTACA GENOMICS成功簽訂大額銷售協議 海外市場成收入新引擎
格隆匯 09-26 18:31

貝康醫療-B(02170.HK)今日盤後發佈公吿,宣佈其全資子公司Genea Biomedx Pty Ltd近期與Gattaca Genomics LLC訂立了買賣協議。Genea Biomedx預計將在兩年內向Gattaca出售Geri®全時差培養箱以及相關耗材軟件等。Gattaca計劃全球開設約100個活躍站點,每個活躍站點都將安裝一套或多套Geri®全時差培養箱。公開資料顯示貝康醫療旗下的Geri®全時差培養箱(國械注進20202180490)為全球首台濕式時差培養箱,可以為胚胎髮育提供穩定的滲透壓環境。

據悉,Gattaca是美國生殖遺傳醫療器械市場的知名企業,致力於在打造一個垂直整合的體外受精生育治療平台,涵蓋基因檢測實驗室、卵子╱精子庫、診所及研究中心。

本次銷售有望(i)大幅擴大Geri®全時差培養箱在現有及新客户中的安裝量,從而增加交叉銷售貝康管線內其他產品和服務的機會,及(ii)鞏固貝康旗下Genea Biomedx在Gattaca業務網絡內的立足點,從而令Genea Biomedx得以擴大在冷凍儲存解決方案、基因測序儀及耗材領域的市場影響力並進一步釋放協同效應。

目前,全球輔助生殖市場規模巨大,歐美等發達國家市場對高質量醫療器械的需求持續增長,新興市場如東南亞、南美洲等地區也呈現出巨大的市場潛力,為貝康提供了廣闊的發展空間。貝康憑藉清晰的國際化戰略、自主創新和外延收購併重、建立全球營銷服務網絡,海外市場正成為貝康收入增長新引擎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account